Ron Renaud

Chief Executive Officer, Kailera Therapeutics

Waltham, United States

Ron Renaud is President and Chief Executive Officer of Kailera Therapeutics, developing next-generation GLP-1 therapies for obesity. Over the prior decade he led three biotech companies to acquisitions worth a combined 16 billion dollars: Idenix Pharmaceuticals (sold to Merck, 2014), Translate Bio (sold to Sanofi, 2021), and Cerevel Therapeutics (sold to AbbVie for 8.7 billion dollars, 2024). Between Cerevel and Kailera, he served as a Partner at Bain Capital Life Sciences.

Expertise

• Biotechnology
• Pharmaceuticals
• M&A